VEGFA and glioblastoma: This discovery led to the FDA approval of bevacizumab, a monoclonal antibody that targets VEGF-A on the surface of endothelial cells and blocks its interaction with its receptors VEGFR1 and VEGFR2, becoming the first FDA-approved targeting therapy for use in recurrent GBM.